8-K: Health Catalyst Stockholders Approve Key Governance Changes and Director Elections at Annual Meeting

Health Catalyst, Inc. announced that its stockholders approved all four proposals at the Annual Meeting, including the election of two Class III directors, ratification of Ernst & Young LLP as independent auditors, approval of executive compensation, and an advisory vote to declassify the Board of Directors.

Summary

• Health Catalyst, Inc. held its annual meeting of stockholders on July 9, 2025, with 53,125,841 shares present or represented by valid proxy out of 69,601,233 shares entitled to vote.
• Stockholders elected Duncan Gallagher and Dr. Jill Hoggard Green as Class III directors to serve three-year terms expiring at the 2028 annual meeting.
• Duncan Gallagher received 37,136,561 votes For and 9,402,545 votes Withheld.
• Dr. Jill Hoggard Green received 45,320,332 votes For and 1,218,774 votes Withheld.
• The appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified with 53,070,196 votes For.
• The advisory, non-binding proposal to approve the compensation of the company's named executive officers was approved with 45,000,705 votes For.
• The advisory, non-binding proposal to approve the Board of Directors initiating action to declassify the Board of Directors was approved with 46,174,256 votes For.

Sentiment

Score: 8

Explanation: The overall sentiment is positive as all management-backed proposals passed with strong shareholder support, including a significant corporate governance enhancement (board declassification). The only minor negative was a higher 'withheld' vote for one director, but it did not prevent his election.

Positives

• All four proposals presented at the Annual Meeting were approved by stockholders, indicating strong shareholder alignment with management and board recommendations.
• The election of both nominated directors, Duncan Gallagher and Dr. Jill Hoggard Green, ensures continuity and stability in board leadership.
• Overwhelming ratification of Ernst & Young LLP as the independent auditor demonstrates confidence in the company's financial oversight.
• Strong approval of executive compensation suggests shareholder satisfaction with the current compensation structure and performance incentives.
• The advisory approval for board declassification aligns the company with modern corporate governance best practices, potentially enhancing accountability and responsiveness to shareholders.

Negatives

• Duncan Gallagher's election had a notable number of votes withheld (9,402,545) compared to Dr. Jill Hoggard Green (1,218,774), indicating some level of shareholder dissent or concern regarding his re-election, though he was still elected.

Future Outlook

The advisory approval for the Board of Directors to initiate action to declassify the Board suggests a future transition from a staggered board structure to one where all directors are elected annually, which is a significant corporate governance shift.

Industry Context

The approval of the advisory proposal to declassify the Board of Directors aligns Health Catalyst with a growing trend in corporate governance, where many public companies are moving away from staggered boards towards annual elections for all directors. This trend is often driven by shareholder advocacy for increased accountability and responsiveness from boards.

Comparison to Industry Standards

• The move towards board declassification is consistent with best practices advocated by institutional investors and proxy advisory firms, who often view declassified boards as enhancing accountability and shareholder rights. Many S&P 500 companies have already declassified their boards, making Health Catalyst's move a step towards aligning with broader market governance standards.
• The strong approval rates for director elections and executive compensation are generally indicative of healthy shareholder relations, comparable to well-governed companies in the healthcare technology sector.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The approval of all proposals, particularly the advisory vote for board declassification, indicates a responsive management team and a move towards enhanced corporate governance, which generally benefits shareholders through increased accountability.
• Management: The strong approval of executive compensation suggests shareholder confidence in the current management team's performance and compensation structure.
• Employees: No direct impact mentioned, but stable governance and positive shareholder relations can contribute to a stable corporate environment.

Next Steps

• The Board of Directors is expected to initiate action to declassify the Board, following the advisory approval from stockholders.
• The newly elected Class III directors, Duncan Gallagher and Dr. Jill Hoggard Green, will serve three-year terms until the 2028 annual meeting.

Key Dates

Recommendation

Keywords

Health Catalyst, Annual Meeting, Stockholder Vote, Board of Directors, Director Election, Corporate Governance, Board Declassification, Executive Compensation, Auditor Ratification, SEC Filing, 8-K